Stelios Papadopoulos, Director at Regulus Therapeutics Inc. (RGLS), bought 500,000 shares at $1.20 ($609K) on 2017-03-21, disclosed to the SEC on 2017-03-23.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.20 | 200,000 | $240K | 39.4% |
| 2 | $1.23 | 300,000 | $369K | 60.6% |
| Total | $1.22 avg | 500,000 | $609K | 100% |
| Filing → |
| EXEL | SELL | 2024-05-22 | $240K | — | Filing → |
| EXEL | SELL | 2022-02-24 | $3.3M | — | Filing → |
| EXEL | SELL | 2021-05-13 | $911K | — | Filing → |